Inhibition of IFN-γ signaling by an Epstein-Barr virus immediate-early protein

Immunity

Volumn 15, Issue 5, 2001, Pages 787-799

  Morrison, Thomas E ^a,b   Mauser, Amy ^a   Wong, Athena ^a   Ting, Jenny P Y ^a,b   Kenney, Shannon C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS IMMEDIATE EARLY PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; EPSTEIN BARR VIRUS; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS IMMUNITY; VIRUS INFECTION;

EID: 0035652377     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(01)00226-6     Document Type: Article

References (76)

1. Modulation of major histocompatibility class II protein expression by varicella-zoster virus
2. The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein
3. The Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia (PML) bodies
4. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases
5. Concomitant in vivo production of 19 different cytokines in human tonsils
6. Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA
7. The IFN-γ receptor: A paradigm for cytokine receptor signaling
8. Initial and innate responses to viral infections-pattern setting in immunity or disease
9. Cellular responses to interferon-γ
10. Characterization of herpes simplex virus type-I infection and herpetic stromal keratitis development in IFN-gamma knockout mice
11. Gamma interferon (IFN-γ) receptor null-mutant mice are more susceptible to herpes simplex virus type I infection then IFN-γ ligand null-mutant mice
12. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: Activation of transforming growth factor βigh3 (TGF-βigh) and TGF-β1
13. The Epstein-Barr virus bZip transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors
14. The Epstein-Barr virus Zta transactivator: A member of the bZip family with unique DNA-binding specificity and dimerization domain that lacks the characteristic heptad leucine zipper motif
15. The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to a loss of BamHI-Q promoter activity
16. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter
17. The biology of Epstein-Barr virus: Lessons learned from the virus and the host
18. Epstein-Barr virus infection
19. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts
20. Activation of expression of latent Epstein-Barr virus after gene transfer with a small cloned fragment of heterogeneous viral DNA
21. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators
22. Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor
23. Epstein-Barr virus BZLF1 transactivator specifically binds to consensus AP1 sites and is related to c-fos
24. Trans-acting requirements for replication of Epstein-Barr virus oriLyt
25. Replication of Epstein-Barr virus oriLyt: Lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays
26. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1
27. Characterization of the Epstein-Barr virus BZLF1 protein transactivator domain
28. RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism
29. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway
30. Transcriptional synergy and interference between the EBV transcription factors EB1 and R require both the basic region and the activation domains of EB1
31. Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription
32. The bZip transactivator, BZLF1, of Epstein-Barr virus functionally and physically interacts with the p65 subunit of NFκB
33. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen
34. The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16
35. Class II transactivator: Mastering the art of major histocompatibility expression
36. Murine cytomegalovirus inhibits interferon-γ-induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II-associated genes
37. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner
38. Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo
39. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators
40. Epstein-Barr virus and its replication
41. The BZLF1 protein of EBV has a coiled coil dimerization domain without a heptad leucine repeat but homology to the C/EBP leucine zipper
42. Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons
43. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor
44. Epstein-Barr virus infection and replication in a human epithelial cell system
45. Responsiveness of the Epstein-Barr virus mediated not I repeat promoter to the Z transactivator is mediated in a cell-type specific manner by two independent signal regions
46. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome
47. Late phase inhibition of murine cytomegalovirus replication by synergistic interaction of interferon-gamma and tumor necrosis factor
48. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway
49. The growing family of interferon regulatory factors
50. Requirement for natural killer cell-produced interferon-γ in defense against murine cytomegalovirus infection and enhancement of this pathway by interleukin 12 administration
51. Structure and function of the Epstein-Barr virus BZLF1 protein
52. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon
53. Interferon γ regulates acute and latent murine cytomegalovirus infection and chronic diseases of the great vessels
54. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1
55. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes
56. Epstein-Barr virus
57. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle
58. A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator
59. A transcription factor with homology to the Ap1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus
60. Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells
61. Activation of transcription by IFN-γ: Tyrosine phosphorylation of a 91-kD DNA binding protein
62. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ
63. Interferon-induced nuclear signaling by Jak protein tyrosine kinases
64. Epstein-Barr virus replication in oropharyngeal epithelial cells
65. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DRβ chain and inhibits antigen presentation
66. How cells respond to interferons
67. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
68. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor
69. Trans-activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EB DNA fragment
70. Activated lymphocytes during acute Epstein-Barr virus infection
71. Viral subversion of the immune system
72. The Epstein-Barr virus immediate-early protein EB1 activates transcription from different responsive elements including AP-1 binding sites
73. Induction of lytic Epstein-Barr virus infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo
74. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism
75. Functional and physical interaction between p53 and BZLF1: Implications for Epstein-Barr virus latency
76. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription